U.S. MARKETS FOR NONVASCULAR STENTS

140 Pages | 37 Exhibits | 2011 Analysis | Forecasts Through 2014

OVERVIEW:
Nonvascular stenting has been used for decades in the palliation of transient and chronic obstructions of natural circulatory pathways that enable the transfer of air, bodily fluids, and other substances involved in systemic metabolic and energy exchange. These circulatory pathways include the biliary tree as well as the gastrointestinal (GI), pulmonary, and urinary tracts. In 2010, nonvascular stenting systems were used in approximately 516,500 endoluminal recanalization procedures in the U.S., generating an estimated $168.8 million in related sales. Over the forecast period covered by this report, the number of nonvascular stenting procedures in the U.S. is expected to increase at a compound annual rate of 1.5%; during the same period, corresponding dollar sales are expected to increase at a compound annual rate of 2.8%, reaching approximately $189.2 million in the year 2014.

This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. nonvascular stents market. Major topics covered by this report include a discussion of current and emerging nonvascular stenting technologies; a clinical overview of nonvascular conditions targeted by stenting (e.g., biliary GI, pulmonary, and urinary tract obstruction) and an analysis of the procedure volumes and market forecasts for biliary, GI, pulmonary, and urologic stenting systems in the U.S.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

a. Nonvascular Stenting Systems 
b. Stent Design and Materials 
c. Products and Procedures 
	i. Biliary Stenting 
	ii. Gastrointestinal Stenting 
	iii. Pulmonary Stenting 
	iv. Urologic Stenting 
	v. Combined Procedure Volumes Forecast 
d. Market Analysis 
	i. Biliary Stents 
	ii. Gastrointestinal Stents 
	iii. Pulmonary Stents 
	iv. Urologic Stents 
	v. Combined Market Analysis 

Exhibit ES-1: 2010, Estimated Incidence of Nonvascular Conditions Targeted by Stenting Technologies 
Exhibit ES-2: Nonvascular Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit ES-3: Nonvascular Stenting Systems, Market Forecast, 2009-2014 

1. CURRENT AND EMERGING PERIPHERAL VASCULAR AND NONVASCULAR STENTING TECHNOLOGIES

1.1 Stent Design 
	1.1.1 Vascular Stents 
	1.1.2 Nonvascular Stents 
	1.1.3 Stent Deployment Mechanisms 
1.2 Stent Materials 
	1.2.1 Metal Stents 
		1.2.1.1 Absorbable Magnesium Alloys 
		1.2.1.2 Cobalt Alloys 
		1.2.1.3 Nickel-Titanium Alloys 
		1.2.1.4 Stainless Steel 
	1.2.2 Standard Polymeric Stents 
	1.2.3 Biodegradable Polymeric Stents 
1.3 Stent Coatings 
	1.3.1 Radiopacity Enhancement 
	1.3.2 Biocompatibility Enhancement 
	1.3.3 Active Therapeutic Enhancement 
		1.3.3.1 Drug-Eluting Stents 
			1.3.3.1.1 Antirestenotic Drug-Eluting Stents 
			1.3.3.1.2 Drug Delivery Techniques 
	1.3.4 Stent Coverings and Linings 

Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent Requirements 
Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent Designs 
Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials 
Exhibit 1-4: Selected Polymeric Stent Materials 
Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents 
Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents 

2. CLINICAL OVERVIEW OF NONVASCULAR STENTS

2.1 Nonvascular Conditions Targeted by Stenting 
	2.1.1 Biliary Tract Obstruction 
		2.1.1.1 Clinical Indications 
		2.1.1.2 Implantation Techniques 
		2.1.1.3 Biliary Stent Types 
			2.1.1.3.1 Plastic Devices 
			2.1.1.3.2 Metal Devices 
		2.1.1.4 Procedure Volumes 
	2.1.2 Gastrointestinal Tract Obstruction 
		2.1.2.1 Colorectal Stenting 
			2.1.2.1.1 Clinical Indications 
			2.1.2.1.2 Technology 
			2.1.2.1.3 Implantation Techniques 
		2.1.2.2 Esophageal Stenting 
			2.1.2.2.1 Technology 
			2.1.2.2.2 Implantation Techniques 
		2.1.2.3 Procedure Volumes 
	2.1.3 Pulmonary Tract Obstruction 
		2.1.3.1 Clinical Indications 
		2.1.3.2 Types of Pulmonary Stenting Systems 
		2.1.3.3 Procedure Volumes 
	2.1.4 Urinary Tract Obstruction 
		2.1.4.1 Ureteral Obstruction 
			2.1.4.1.1 Urinary Stone Disease 
			2.1.4.1.2 Ureteral Strictures 
			2.1.4.1.3 Ureteral Stenting 
		2.1.4.2 Urethral Obstruction 
			2.1.4.2.1 Benign Prostatic Hyperplasia 
			2.1.4.2.2 Urethral Strictures 
			2.1.4.2.3 Urethral Stenting 
		2.1.4.3 Procedure Volumes 

Exhibit 2-1: 2010, Biliary Obstruction, Facts and Figures 
Exhibit 2-2: Biliary Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit 2-3: 2010, Colorectal Obstruction, Facts and Figures 
Exhibit 2-4: 2010, Esophageal Obstruction, Facts and Figures 
Exhibit 2-5: Gastrointestinal Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit 2-6: 2010, Pulmonary Tract Obstruction, Facts and Figures 
Exhibit 2-7: Pulmonary Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit 2-8: 2010, Upper Urinary Tract Obstruction, Facts and Figures 
Exhibit 2-9: 2010, Lower Urinary Tract Obstruction, Facts and Figures 
Exhibit 2-10: Urologic Stenting, Procedure Volumes Forecast, 2009-2014 

3. NONVASCULAR STENTS MARKET

	3.2.1 Biliary Stenting Systems 
		3.2.1.1 Products 
		3.2.1.2 Market Forecast 
		3.2.1.3 Competitive Analysis 
	3.2.2 Gastrointestinal Stenting Systems 
		3.2.2.1 Products 
		3.2.2.2 Market Forecast 
		3.2.2.3 Competitive Analysis 
	3.2.3 Pulmonary Stenting Systems 
		3.2.3.1 Products 
		3.2.3.2 Market Forecast 
		3.2.3.3 Competitive Analysis 
	3.2.4 Urologic Stenting Systems 
		3.2.4.1 Ureteral Stenting Products 
		3.2.4.2 Urethral Stenting Products 
		3.2.4.3 Market Forecast 
		3.2.4.4 Competitive Analysis 

Exhibit 3-1: Nonvascular Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit 3-2: Nonvascular Stents, Market Forecast, 2009-2014 
Exhibit 3-3: 2011, Selected Metal and Plastic Biliary Stents 
Exhibit 3-4: Biliary Stents, Market Forecast, 2009-2014 
Exhibit 3-5: 2010, Biliary Stents Market, Share by Supplier 
Exhibit 3-6: 2011, Selected Colorectal Stents 
Exhibit 3-7: 2011, Selected Esophageal Stents 
Exhibit 3-8: Metal Gastrointestinal Stents, Market Forecast, 2009-2014 
Exhibit 3-9: 2010, Colorectal Stents Market, Share by Supplier 
Exhibit 3-10: 2010, Metal Esophageal Stents Market, Share by Supplier 
Exhibit 3-11: 2011, Selected Pulmonary Stents 
Exhibit 3-12: Pulmonary Stents, Market Forecast, 2009-2014 
Exhibit 3-13: 2010, Pulmonary Stents Market, Share by Supplier 
Exhibit 3-14: 2011, Selected Ureteral Stents 
Exhibit 3-15: 2011, Selected Prostatic Stents 
Exhibit 3-16: Urologic Stents, Market Forecast, 2009-2014 
Exhibit 3-17: 2010, Ureteral Stents Market, Share by Supplier 
Exhibit 3-18: 2010, Urethral Stents Market, Share by Supplier 

4. COMPANY PROFILES

4.1 AbbeyMoor Medical, Inc. 
4.2 American Medical Systems, Inc. 
4.3 Boston Scientific Corporation 
4.4 Bryan Corporation 
4.5 Cook Group, Inc. 
4.6 Cordis Corporation/Johnson & Johnson 
4.7 Gyrus ACMI/Olympus Corporation 
4.8 Hood Laboratories, Inc. 
4.9 Merit Endotek/Merit Medical Systems, Inc. 

Appendix:  Company Listing


COMPANIES COVERED:

  1. AbbeyMoor Medical, Inc.
  2. American Medical Systems, Inc.
  3. Boston Scientific Corporation
  4. Bryan Corporation
  5. Cook Group, Inc.
  6. Cordis Corporation/Johnson & Johnson
  7. Gyrus ACMI/Olympus Corporation
  8. Hood Laboratories, Inc.
  9. Merit Endotek/Merit Medical Systems, Inc.
Contact Us

Need help finding medtech research? Let us help you!